GenMont BiotechTPE:3164 +0.30%82 EV-to-FCF is 17.44 as of Jul. 08, 2026, which is 8% above its 10-year median of 16.22. GuruFocus rates TPE:3164 with a GF Score™ of 82/100 and a GF Value™ of NT$26.24 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 327 Biotechnology companies, GenMont Biotech ranks worse than 50.76% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, GenMont Biotech's Enterprise Value is NT$1,219.8 Mil.
GenMont Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$69.9 Mil. Therefore, GenMont Biotech's EV-to-FCF for today is 17.44.
The historical rank and industry rank for GenMont Biotech's EV-to-FCF or its related term are showing as below:
TPE:3164'
s EV-to-FCF Range Over the Past 10 Years
Min: -2098.73 Med: 16.22 Max: 216.77
Current: 17.13
During the past 13 years, the highest EV-to-FCF of GenMont Biotech was 216.77. The lowest was -2098.73. And the median was 16.22.
TPE:3164's EV-to-FCF is ranked worse than 50.76% of 327
companies
in the Biotechnology industry
Industry Median: 16.69
vs TPE:3164: 17.13
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
GenMont Biotech's PE Ratio (TTM) for today is calculated as:
GenMont Biotech's share price for today is NT$16.55.
GenMont Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.660.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
GenMont Biotech EV-to-FCF Related Terms
GenMont Biotech EV-to-FCF Historical Data
* Premium members only.
The historical data trend for GenMont Biotech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:3164 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, GenMont Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GenMont Biotech EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GenMont Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where GenMont Biotech's EV-to-FCF falls into.
GenMont Biotech's current Enterprise Value is NT$1,219.8 Mil.
GenMont Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$69.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenMont Biotech (TPE:3164) has a EV-to-FCF of 17.44 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on GenMont Biotech and its competitors. This is near median its historical median of 16.22. According to the industry distribution chart, GenMont Biotech ranks #166 out of 327 companies in the Biotechnology industry, placing it in the top 50.8%.
Is GenMont Biotech's EV-to-FCF too high?
GenMont Biotech's current EV-to-FCF of 17.44 is near median its 10-year median of 16.22. The Biotechnology industry median EV-to-FCF is 16.69. GenMont Biotech's value of 17.44 is 4.5% above this industry median. Based on the distribution chart, GenMont Biotech ranks #166 out of 327 companies in the Biotechnology industry, which is below the industry midpoint. Overall, GenMont Biotech has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GenMont Biotech's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GenMont Biotech ranks #166 out of 327 companies for EV-to-FCF. This places GenMont Biotech in the lower half of its industry. The industry median EV-to-FCF is 16.69. GenMont Biotech's value of 17.44 is 4.5% above this benchmark. While the company's 10-year median is 16.22 vs. the industry median of 16.69, GenMont Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.69, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GenMont Biotech's current EV-to-FCF of 17.44 is 4.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on GenMont Biotech and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GenMont Biotech's current EV-to-FCF is 17.44, which is near median its own 10-year median of 16.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenMont Biotech stock overvalued right now?
Based on GuruFocus' analysis, GenMont Biotech (TPE:3164) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$26.24, compared to a current price of NT$16.55 — trading 36.9% below its estimated fair value. The current EV-to-FCF is 17.44, which is near median its 10-year median of 16.22 and 4.5% above the Biotechnology industry median of 16.69. GenMont Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For GenMont Biotech (TPE:3164), the current EV-to-FCF is 17.44 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GenMont Biotech (TPE:3164) Overvalued in 2026?
Based on GuruFocus' analysis, GenMont Biotech stock appears to be undervalued.
The current stock price of NT$16.55 is trading 36.9% below its estimated GF Value™ of NT$26.24.
GuruFocus considers GenMont Biotech to be Significantly Undervalued.
Key valuation signals for TPE:3164:
EV-to-FCF: 17.44 (near median its 10-year median of 16.22)
GF Value™: NT$26.24 vs. price of NT$16.55 (36.9% below fair value)
Industry Position: 4.5% above the Biotechnology median (#166 of 327)
No single metric tells the full story. See the TPE:3164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenMont Biotech Inc is engaged in the research, development, manufacturing, and selling of a variety of probiotic supplements. The Group mainly engages in the manufacturing and selling of functional foods, its single operating segment.
82GF Score
Get the complete analysis for TPE:3164
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:3164 has been successfully added to your 
